{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022588","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.274652+00:00","generated_at":"2026-06-22T05:26:18.292216+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Xenon Pharma appoints Andrea DiFabio as Chief Legal Officer and Corporate Secretary","bullets":["Andrea DiFabio joined Xenon as Chief Legal Officer and Corporate Secretary effective Nov 7, 2022.","She previously served as Chief Legal & Admin Officer at Repertoire Immune Medicines (2020-2022).","DiFabio held CLO roles at Codiak Biosciences and Bioverativ; earlier experience at Biogen and Parexel.","She will lead global legal strategy as Xenon advances late-stage epilepsy clinical programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022588","json":"https://secwatch.observer/filing/0000950170-22-022588.json","markdown":"https://secwatch.observer/filing/0000950170-22-022588.md","text":"https://secwatch.observer/filing/0000950170-22-022588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017022022588/0000950170-22-022588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017022022588/xene-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:26:18.292216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}